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Abstract
Human small cell lung cancer (SCLC) is highly aggressive, and quickly develops resistance to therapy. SCLC cells are typically
insensitive to glucocorticoids due to impaired glucocorticoid receptor (GR) expression. This is important as we have previously
shown that expression of a GR transgene induces cell death in-vitro, and inhibits tumor growth in-vivo. However, the
underlying mechanism for loss of GR expression is unknown. The SCLC cell line, DMS79, has low GR expression, compared to
non-SCLC cell lines and normal bronchial epithelial cells. Retroviral GR expression in DMS79 cells caused activation of the
apoptotic pathway as evidenced by marked induction of caspase-3 activity. Methylation analysis of the GR promoter revealed
some methylation in the 1D, and 1E promoters of the GR gene, however the ubiquitous constitutively active 1C promoter was
heavily methylated. In the 1C promoter there was a highly significant increase in DNA methylation in a panel of 14 human
SCLC cell lines compared to a mixed panel of GR expressing, and non-expressing cell lines, and to peripheral blood
mononuclear cells. Furthermore, within the panel of SCLC cell lines there was a significant negative correlation seen between
methylation of the 1C promoter, and GR protein expression. Reversal of GR gene methylation with DNA methyltransferase
inhibition caused increased GR mRNA and protein expression in SCLC but not non-SCLC cells. This resulted in increased Gc
sensitivity, decreased Bcl-2 expression and increased caspase-3 activity in SCLC cells. These data suggest that DNAmethylation
decreases GR gene expression in human SCLC cells, in a similar manner to that for conventional tumor suppressor genes.
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Introduction
Changes in the epigenetic status of genes are important in many
human diseases, but particularly in cancer [1]. Some of these are
mediated by changes in the expression and activity of DNA
methyltransferases, DMNT1, DNMT3A and DNMT3B [2,3].
Cancer cells characteristically have hypermethylated CpG islands
associated with tumor suppressor genes [1], and DNMT1 is reported
to be over-expressed in lung cancer patients who smoke [4]. Recent
studies have identified that a tobacco smoke carcinogen, nitrosamine
4-(methylnitrosamino)-1-(3-pyridyl)1-butanone (also known as nico-
tine derived nitrosamine ketone; NNK) not only induces gene
mutations, but also increases hypermethylation of multiple tumor
suppressor gene promoters including cyclin dependent kinase
inhibitor 2A (p16ink4a), death associated protein kinase 1 (dapk1),
and retinoic acid receptor b (rarb) [4]. Smoking is the major risk factor
for human small cell lung carcinoma, and smoking is itself associated
with methylation of more than 20 tumor suppressor genes [5,6].
Many factors can affect glucocorticoid sensitivity, including
genetic variation at the GR gene locus, and expression of interacting
proteins [7–10]. We have previously shown that human SCLC cell
lines are resistant to glucocorticoid (Gc) hormones and drugs and
that this resistance is due to impaired GR expression [11,12].
Restoration of GR expression in the cells by transfection, or viral
transduction is sufficient to restore Gc sensitivity [12]. However,
more importantly, restoration of GR expression is also sufficient to
induce apoptosis of SCLC cells both in-vitro [13], and also in a
xenograft model [14]. This raises the possibility that GR is a novel
tumor suppressor gene for SCLC, and that loss of GR expression is
implicated in SCLC pathogenesis.
The GR gene (NR3C1) is a ubiquitously expressed, ligand
activated transcription factor, a member of the nuclear receptor
superfamily. There is a single copy gene on chromosome 5, but its
structure is complex, and relatively little is known about how
transcription is regulated from it [15]. Transcription is controlled
by 9 promoters, each associated with an alternative transcription
start site. Seven of these promoters are clustered together in a CpG
island, a common feature of housekeeping genes [16]. All
transcripts generate authentic full-length GR protein as the
translation start site is located in the common exon 2.
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The GR is activated by Gc hormones from the adrenal cortex,
under tight control of the hypothalamic-pituitary-adrenal (HPA)
axis. This axis is under feedback control at the hippocampus and
hypothalamus through activation of GR protein expressed in these
sites. Variability in rat HPA axis tone has been ascribed to changes
in hippocampal GR expression, regulated by altered methylation
of the rat GR exon 1–7 promoter [17]. This is located, as in the
human, in the upstream CpG island. More recent studies have
examined methylation status of a number of alternate human GR
promoters in peripheral blood mononuclear cells [16]. These
studies have revealed extensive, and variable methylation.
Hippocampal and hypothalamic GR plays a key role in the
negative feedback control of the hypothalamic-pituitary-adrenal axis.
Altered GR expression in the brain results in re-setting of the tone of
this neuroendocrine axis and this is associated with altered
methylation of nerve growth factor inducible-A (NGFI-A, or KROX,
EGR1) binding site in the rat exon 1.7 promoter, homologous to the
human exon 1F promoter [17–19]. This methylation controlled
alteration in GR expression results in consequences for the whole
organism, by regulating adrenal glucocorticoid production.
In this study we examined the pattern of GR promoter
methylation in human SCLC cells, and showed that reversal of the
methyl marks increased GR protein expression, and function.
Moreover, we identified a negative correlation between GR 1C
promoter methylation and GR protein expression across a panel of
human SCLC cell lines, and human control cells.
Materials and Methods
Cell Culture and Maintenance
A549 human lung epithelial carcinoma cells, HEK-293 human
embryonic kidney cells, HeLa human cervical carcinoma cells and
U20S human osteosarcoma cells (European Collection of Cell
Cultures, Wiltshire, UK) were all cultured in DMEM (Invitrogen)
supplemented with 10% fetal calf serum (FCS) (Invitrogen).
Non-small cell lung cancer lines NCI-H358 and –H727
(European Collection of Cell Cultures, Wiltshire, UK) and NCI-
H23, -H441, -H1299 (American Type Culture Collection, USA)
were grown in RPMI 1640 medium (Invitrogen) supplemented
with 10% FCS and 10 mM HEPES as recommended by supplier.
Small Cell Lung Cancer (SCLC) cell lines used in this study
were the 10‘COR’ cell lines Cor L24, Cor L27, Cor L31, Cor L32,
Cor L42, Cor L47, Cor L51, Cor L88, Cor L99 and Cor L103.
Also used were DMS 79, DMS 153, HC12 and HX 148. All of
these cell lines were derived from patients with pathologically
confirmed SCLC [20,21] with the exception of Cor L32, which
was derived from a patient with poorly differentiated squamous
carcinoma of the lung. This cell line did however exhibit the
characteristics of SCLC [21]. All SCLC cell lines were cultured in
RPMI 1640 medium (Invitrogen) supplemented with 10% FCS
and 10 mM HEPES, as previously described [12].
Human peripheral blood mononuclear cells were obtained from
healthy local donors, according to LREC approval 09/H1013/6.
Normal human bronchial epithelium was harvested from lung
resection specimens after surgery for lung cancer, with full,
informed patient consent.
Treatments
Where appropriate, cells were treated with vehicle or 100 nM
dexamethasone (Sigma-Aldrich) for 24 hours at 37uC, 5% C02
before lysis. In certain experiments, cells were incubated with
vehicle or 5 mM 59Azadeoxycytidine (Sigma-Aldrich) for 72 hours
or 5 days. After treating with 59Azadeoxycytidine some cells were
treated for a further 72 hours with 100 nM dexamethasone.
Immunoblot analysis
Cells were lysed using 16 RIPA buffer (100 mM Tris base,
150 mM NaCl, 1% Igepal, 2.5% sodium deoxycholate, 1 mM
EDTA).This buffer also contained protease inhibitors (Roche).
Following centrifugation for 30 min at 10,000 g supernatants
were harvested and assayed for protein content using a Bradford
assay (Bio-Rad). Samples were then diluted in loading buffer
[0.125 M TrisCl (pH 6.8), 0.1% sodium dodecyl sulphate
(SDS), 20% glycerol, 0.2% b-mercaptoethanol, 0.001% bromo-
phenolblue]. Cell extracts (50 mg) were then analysed by SDS-
PAGE and western blotting as described [22,23]. Primary
antibodies used were the mouse monoclonal anti-hGR (Clone
41, 1:2500), which binds in the N-terminal region of GR (BD
Biosciences), rabbit polyclonal anti-hGR (P-20, 1:500) raised
against a peptide mapping at the C-terminus of GRa (Santa
Cruz) and the mouse monoclonal a–tubulin (1:5000) (Sigma-
Aldrich). Secondary antibodies used were the horseradish
peroxidase-conjugated anti-mouse (1:5000) and anti-rabbit
(1:5000) (GE Healthcare). To quantify protein levels, densito-
metric analysis was carried out. Blots were scanned and the
densitometry of each band was analysed using ImageJ software.
The internal loading control (aTubulin) was also quantified and
the results were normalised against these readings. This analysis
was carried out on 3 separate blots for each experiment and the
average calculated.
Reporter Gene Assays
Cells were co-transfected with 2 mg of a TAT3-luciferase
construct [13] and 0.5 mg of a pCMV-Renilla Luciferase construct
(to correct for transfection efficiency) using Fugene 6 (Roche). In
some cases, cells were also transfected with 1 mg of a GR
expression vector (pFUNC1-GR-eYFP) [13]. Cells were treated
with dex as described before luciferase assays were carried out
using the Dual Luciferase Reporter Assay System (Promega), as
previously described [8].
Retroviral infections
pFUNC1-eYFP or pFUNC1-GR-eYFP were transfected into
HEK293 for retroviral production using Fugene HD (Roche, UK),
as a transfection reagent at a 3:2 reagent:DNA ratio. Infection of
the retroviral particles into DMS 79 cells was performed as
detailed before. Post infection, cells were cultured in normal
growth media containing serum for 72 hours.
Cleaved caspase-3 assay
DMS 79 cells expressing GR-eYFP or eYFP were applied to
poly-L-lysine coated cover slips and fixed with 4% formaldehyde.
Cells were permeabilized with PBS/0.2% Triton-6100. After
washing, cells were blocked in PBS/0.1% Tween-20+5% donkey
serum. Anti-ACTIVE Caspase-3 pAb (Promega, UK) diluted
1:250 in blocking buffer was added to cells and incubated
overnight. Secondary antibody incubation was performed in the
dark using Alexa Fluor 546 donkey anti-rabbit IgG (Invitrogen,
UK) diluted 1:500 in PBS. Cover slips were mounted using
ProLong Gold with DAPI (Invitrogen, UK).
Images were collected on an Olympus BX51 upright micro-
scope using a 606/1.40 UPlanApo objective and captured using a
Coolsnap ES camera (Photometrics) through MetaVue Software
(Molecular Devices). Specific band pass filter sets for DAPI, FITC
and Texas red were used to prevent bleed through from one
channel to the next. Images were processed and analysed using
ImageJ (http://rsb.info.nih.gov/ij).
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Sodium Bisulphite Sequencing
Genomic DNA was extracted from several of the cell lines used in
this study, some of which had been treated with 59 Azadeoxycytidine
(see results) using the DNeasy blood and tissue kit (Qiagen). Purified
genomic DNA was then bisulphite converted using the Epitect
Bisulphite Kit (Qiagen). This converted DNA was then used as a
template in PCR reaction to amplify specific GR promoter regions.
GR promoter regions amplified (and the primers used) were as follows:
Promoter
1C (forward- 59-AGGTGGATCCGGAAGGAGGTAGYGA-
GAAAAGAAATT-39; reverse- 59- AGGTGAATTCACACRA-
ACTCRCAAAATAAAAAAAA-39).
Promoter
1D(forward- 59-AGGTGGATCCTTTTATAAAAATTTTT-
TTGGTTGAGG-39; reverse- 59- AGGTGAATTCCCCCCT-
ACTCTAACATCTTAAAAA).
Promoter
1E(forward-59- AGGTGGATCCTTAGAGTTATAAAAAT-
TATAATTTGTGT-39; reverse- 59- AGGTGAATTCATAC-
AAACAACTTTAAAATACCAAC-39).
All primers were supplied by MWG-Eurofins.
PCR was carried out using Immolase Polymerase (Bioline),
following the manufacturer’s instructions. Cycling conditions were
as follows: 95uC for 10 minutes, 30 cycles, at 95uC for 30 seconds,
at 56uC for 45 seconds, and at 72uC for 30 seconds, this was
followed by a final extension of 72uC for 10 minutes.
PCR products were electrophoresed on a poly-acrylamide gel
and purified using a gel extraction kit (Qiagen). Ligations were
then carried out using these PCR fragments using the pGEM-T-
easy vector system (Promega) following the manufacturer’s
instructions. Following transformation into JM-109 competent
bacteria (Promega), colonies were picked and incubated overnight
Figure 1. GR expression is decreased in the SCLC cells compared to non-SCLC cells and bronchial epithelial cells. (A) Western blot
analysis of GR, and tubulin protein expression in U20S, HEK, HeLa, A549 and DMS 79 cells. Blot is representative of 3 separate experiments. (B)
Comparison of GR protein expression between SCLC, and non-SCLC (NS) cell lines. Quantitation of GR expression relative to tubulin is presented as
mean +/2 S.E.M. (n = 3) with * indicating p,0.05, Student’s t-test for independent samples. (C) Comparison of GR protein expression in normal
human bronchial epithelium (NBE) compared to non-SCLC cell line (A549), and a panel of human SCLC cell lines. Quantitation of GR expression
relative to tubulin is presented. Mean of n = 2. (D) Analysis of GR protein expression using a pan-GR antibody raised against the GR N terminal (N-
term), and a GRalpha specific GR antibody raised against the C terminal (C-term).
doi:10.1371/journal.pone.0024839.g001
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in LB broth at 37uC. Mini-preps (Qiagen) were carried out on
these cell suspensions, followed by a restriction digest using EcoRI
(Roche) to confirm the presence of the correct insert. Plasmids
containing the insert were then sent for sequencing using an SP16
primer at the DNA Sequencing Facility, University of Manchester.
An initial study was carried out to analyse potential methylation
and the effects of 59Azadeoxycytidine, using DNA from DMS 79
cells. In this case, one clone was analysed for each condition (each
individual promoter, untreated or treated with 59Azadeoxycyti-
dine). A more in depth study was carried out to analyse
methylation of the 1C promoter in a panel of SCLC cell lines.
In this case, 3 clones were analyzed per cell line.
Statistics
All statistical analysis was carried out using SPSS for Windows
version 16. Further statistical analysis was carried out to compare
Figure 2. Expression of the GR transgene caused apoptosis. (A) DMS 79 cells were infected with either GR-eYFP or eYFP retroviruses and GR
protein assessed at 72 h. (B) DM79 cells treated as above were fixed for immunohistochemistry to detect cleaved caspase-3. Cells were stained for
activated caspase-3 and then analysed for co-localisation with either GR-eYFP or eYFP. Percentage of cells positive for cleaved caspase-3 and eYFP or
GR-eYFP. Cell counts derived from 3 independent infections and represented as percentage of caspase-3 positive to eYFP positive as mean +/2 S.E.M.
(n = 3) with *** indicating p,0.001, Student’s t-test for independent samples.
doi:10.1371/journal.pone.0024839.g002
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methylation levels by Dr Steve Roberts, University of Manchester;
using a linear regression model. The equation used for this analysis
was as follows:
Probability of methylation~
logit(a´zbpositionz bgroup z ucell):
Results
Expression of GR is impaired in the human SCLC cell line,
DMS79
GR protein was measured in the hSCLC cell line, DMS79 and
compared with two Gc sensitive cells lines, HeLa and A549, and
two Gc resistant cells lines, U2OS and HEK293. The SCLC cell
Figure 3. CpG methylation in the GR 1C, 1D, and 1E promoter regions in DMS 79 cells. Bisulphite sequencing was performed on extracted
genomic DNA from DMS 79 cells incubated with 59Azadeoxycytidine for 5 days (untreated as control). The original sequence (obtained from GENOME
Browser) was compared to bisulfite treated DNA from the control and 59Azadeoxycytidine treated samples. Bold, open boxes highlight specific
methylated CpGs, which showed reversal of methylation after 59Azadeoxycytidine incubation. The potential transcription factor binding sites in close
proximity to the methylated sites are indicated by grey shading for Sp1 binding site and dark grey shading for C/EBPb binding site. (A) CpG
methylation in the GR 1D promoter region in DMS 79 cells. Individual CpGs are numbered and in capitals. (B) CpG methylation in a region of the GR
promoter 1E from DMS 79 genomic DNA. Individual CpGs are numbered and in capitals. (C) Genomic DNA from a region of the GR promoter 1C from
DMS 79 cells. Individual CpGs are numbered and in capitals. Italic text indicates the start of exon 1C.
doi:10.1371/journal.pone.0024839.g003
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line DMS79 expresses low levels of GR protein, similar to the U2OS
cells, and clearly far less than the HeLa and A549 cells (Fig. 1a).
Comparison with a panel of non-SCLC cell lines indicates that
expression of GR is lower in the SCLC cells (Fig. 1b). GR protein
was found to be expressed in normal human bronchial epithelium,
harvested from lung tissue at resection of lung cancer (Fig. 1c).
GR migrated as two major species, and the relative abundance
appeared to differ between cell types (Fig. 1a,b). This may reflect
alternative splicing to the GRb isoform, or alternative translation
start site usage [22–24]. To further characterize the species,
immunoblots were repeated using a C terminal specific antibody
that specifically recognizes GRa (Fig. 1d). The similar banding
pattern observed with the two antibodies indicates both proteins
share a common C terminal domain, suggesting that the protein
diversity lies with alternative translation start site usage.
Restoration of GR expression induces apoptosis
In DMS79 cells expression of a GR-eYFP transgene by retroviral
infection resulted in increased GR-eYFP protein (Fig. 2a) and
apoptosis as evidenced by increased cleaved caspase-3 in the SCLC
Figure 4. CpG methylation of GR 1C promoter in a panel of 14 SCLC Cell lines. Genomic DNA was extracted from (A) specific control cell
lines, including primary peripheral blood mononuclear leucocytes from a healthy donor and (B) 14 hSCLC cell lines. After bisulfite conversion the 1C
promoter region was PCR amplified. 3 clones per cell line were then sequenced. Methylation in the panel of SCLC cell lines and control cell lines is
displayed as ‘‘beads’’. Each individual bead represents a single CpG in the GR 1C promoter in numerical order from left to right. White beads indicate
unmethylated CpGs whilst black beads indicate methylated CpGs. All 3 clones are displayed for each cell line analyzed.
doi:10.1371/journal.pone.0024839.g004
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cells expressing the GR-eYFP (Fig. 2b). In these studies only a
minority of cells are effectively transduced, hence the low
abundance of expressed fusion protein in the pool of cells. In
addition, expression of the transgene induced apoptosis, further
reducing GR-eYFP concentration in pooled cell lysates [13,14].
Methylation status of GR promoter in SCLC cells
The decreased GR expression in SCLC cells may result from
alteration in GR promoter methylation, or from an indirect
mechanism. Therefore methylation status of the GR promoters in
DMS79 cells was examined by bisulfite sequencing. We did not
detect any DNA methylation in the promoters 1B, and 1F. The
1D and 1E promoter each had only a single methyl CpG, marked
with an open box (Fig. 3a,b). In contrast the 1C promoter had four
methyl CpGs (Fig. 3c). The observed methylated CpGs are located
in potential transcription factor binding sites, (CpGs 6, 44 and 52),
or lie close to such a site (CpG 69) (Fig. 3c).
SCLC cell lines have increased methylation of the GR 1C
promoter
To determine if the observed changes in GR promoter
methylation were found in other human SCLC cell lines, a panel
of 14 hSCLC cells lines with varying GR expression were
compared with two GR expressing cell lines, (A549 and HeLa) a
non-expressing cell line, (U2OS), and peripheral blood mononu-
clear cells as a primary cell comparison (Fig. 4a,b). The beads
represent CpG dinucleotides from position 1 to position 69. It is
readily apparent that there is frequent methylation at the last two
beads on the right, which represent CpG 68 and 69. This is
present across the panel of SCLC cells, and is also seen in the
control cells. However, there is also a marked increase in
methylation at positions 1–67 across the SCLC panel, without
any notable clustering. In contrast there is very little CpG
methylation seen at positions 1–67 in the control cell panel
(Fig. 4a,b).
Logistic regression was used to compare methylation between
the SCLC panel, and all the control cells (Table 1). This revealed
that there was a significant difference between groups with
methylation at CpG 69 individually; and with CpG 68 and 69 in
combination, and across the whole promoter region. A significant
difference was also observed between groups for all CpGs
excluding 68 and 69 (Table 1).
GR promoter methylation is correlated with GR
expression
Across all the hSCLC cell lines there was a wide range of GR
expression, although in all cases GR was less abundant than in the
HeLa and A549 control cell lines (Fig. 5a, b). There was also a
marked variation in the abundance of the two GR protein species
across the cell lines examined, but for this analysis both GR
protein isoforms were considered together. The relationship
between GR 1C promoter methylation and GR protein expression
was examined across the whole panel of hSCLC cell lines. There
was a significant correlation between number of methylated CpGs,
and the GR protein expression within the panel of hSCLC cell
lines; r2 = 0.54, and p= 0.01 (Fig. 5c).
Restoration of GR expression by reversal of DNA
methylation
If the loss of GR expression in DMS79 cells resulted from DNA
methylation, perhaps consequent to carcinogenesis, GR expression
would be predicted to increase following reversal of methylation.
After 72 hours of treatment with 59Azadeoxycytidine, GR mRNA
levels increased dramatically in DMS79 cells when compared to
HEK and A549 cells where no changes in expression were seen
(Fig. 6a). Furthermore, after 72 hours, or after 5 days incubation
with 59Azadeoxycytidine, there was a striking increase in GR
protein (Fig. 6b). In contrast to the increase in GR expression seen
in DMS79, there was decreased expression in U2OS cells, possibly
due to toxicity (Fig. 6b).
The effect of 59Azadeoxycytidine was then compared in human
SCLC cell lines and non-SCLC cell lines to determine if the
regulation of GR expression by methylation was widespread in
lung cancer. Three of the four SCLC cell lines showed augmented
GR expression after 59Azadeoxycytidine treatment, in comparison
to only one of the four non-SCLC cell lines (Fig. 6c).
The increase in GR expression seen in DMS79 cells is predicted
to restore Gc sensitivity to these cells. Indeed, there was increased
Gc transactivation of a simple reporter gene (Fig. 7a). The
magnitude of Gc induction was considerably less than that seen
with GR overexpression, but the latter does result in supra-
physiological GR concentrations in target cells (Fig. 7a).
The increased GR expression in response to treatment with
59Azadeoxycytidine resulted in suppression of the pro-survival Bcl-
2 gene in both HEK, and DMS79 cells (Fig. 7b). There was also
increased cleaved caspase-3 activation in the SCLC cells but not
the non-SCLC cells (Fig. 7c & 7d). It is important to note that after
5 days incubation with 59Azadeoxycytidine there was induction of
cell death, possibly due to reacquisition of GR expression, or
regulation of other survival genes.
Discussion
Epigenetic disorders are implicated in many human diseases
including cancer. Cigarette smoke is the principal environmental
agent promoting SCLC and recently, a cigarette smoke carcino-
gen, NNK, has been shown to exert a specific effect promoting
DNMT1 expression, and activity [4]. Therefore this carcinogen
may act by inducing epigenetic changes in key genes implicated in
the pathogenesis of the cancer.
We have previously shown that the glucocorticoid receptor is
effectively a tumor suppressor gene for SCLC, whose expression is
inhibited [12]. We have extended the analysis in this study with
Table 1. Analysis of differences in methylation between SCLC
cell lines and all control cells.
Group effect
Position
effect Cell line effect
Analysis OR (95%CI) P P s
CpG 68 2.4 (0.8 to 7.0) 0.11 - 0.0001
CpG 69 4.5 (1.4 to 14.0) 0.010 - 0.001
CpG 68 and 69 3.3 (1.5 to 7.1) 0.003 0.58 0.0001
CpG ,68 1.8 (1.1 to 3.1) 0.027 0.32 0.23
All CpGs 2.1 (1.3 to 3.4) 0.002 ,0.001 0.22
A logistic regression analysis was carried out to compare methylation in the 14
SCLC cell lines (n = 48) to controls (HeLa, A549, U20S, HEK and PBMC’s) (n = 21
(all 9 A549 clones included)). The group effect is displayed as an odds ratio (OR)
with a 95% confidence interval (CI) for SCLC vs control, with p values ,0.05
regarded as significant. It would be expected that the repeats from each cell
line would be correlated. To handle this a cell-line specific random effect is
included in the model. This effect is parameterised by a single standard
deviation, s. Where multiple sites are analysed the site is included as an
additional covariate, as in a 2-way analysis of variance (position effect).
doi:10.1371/journal.pone.0024839.t001
Glucocorticoid Receptor Methylation in SCLC
PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e24839
further evidence that the GR expression is lower in a panel of
SCLC cells compared to non-SCLC cells or normal bronchial
epithelial cells. Reacquisition of GR expression, and glucocorticoid
sensitivity in SCLC cells in vitro, or in xenograft tumors results in
apoptosis [13,14]. GR is expressed in most cells and tissues, and
exerts pleiotropic effects on cells. However, relatively little is
known of how GR gene expression is regulated, as it has an
unusually complex promoter structure. More recent studies in
primary peripheral blood mononuclear cells defined highly
individual patterns of GR promoter methylation [16]. This work
also mapped potential, and proven transcription factor binding
sites within the promoters, the majority of which contained CpG
sites which could be methylated. This suggested that differential
methylation of the human GR promoter is a mechanism to control
promoter utilization, and so GR gene expression.
Three GR promoters were examined in the index cell line,
DMS79, and all three contained methylated CpG sites. Further
analysis was performed on the 1C promoter as it has been shown
to be ubiquitously expressed in all tissues tested, including lung
[15]. There was an obvious and highly significant increase in CpG
methylation across a panel of hSCLC cell lines compared to the
non-SCLC cell line A549. Importantly there was no increase in
the two non-expressing control cell lines (U2OS and HEK293),
indicating that 1C promoter methylation is not required to limit
GR expression, but that other mechanisms may apply to regulate
GR expression in different cell types. A broader comparison
between hSCLC cells and a heterogeneous panel of GR
expressing, and non-expressing cell lines also found a highly
significant increase in methylated CpG sites in the hSCLC cells. It
was striking that methylation of CpG68 and 69 was far higher
Figure 5. GR expression levels in a panel of hSCLC cell lines. (A) Representative western blot for GR and tubulin in 10 SCLC cell lines as well as
control cell lines HEK (human embryonic kidney), U2OS (osteosarcoma), HeLa (cervical carcinoma) and A549 (non small cell lung carcinoma). (B)
Densitometry was carried out on 5 separate blots to quantify the levels of GR expression relative to tubulin. Graph shows the average, corrected GR
expression 6 S.E.M. (C) Relationship between methylation of GR Promoter 1C and GR expression in a panel of human lung cancer cell lines. Overall
methylation (percentage) across promoter 1C was plotted against GR expression, with standard error, for each cell line. The regression line was
significantly different to zero (P = 0.01), and the goodness of fit was r2 = 0.54.
doi:10.1371/journal.pone.0024839.g005
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across all the cell lines examined than positions ,68. CpG68 lies
within a consensus SP-1 transcription factor binding element, and
CpG69 lies immediately 39 to it. There was no other positional
clustering of the methylated CpG sites, and statistical analysis did
not identify any significant positional effect. Some of the
methylated CpG sites at ,68 overlie consensus transcription
factor binding sites (CpG6, 44 and 52), but CpGs1,2 and 3 did not.
Within the panel of hSCLC cells there was variation in GR
protein expression, which was quantitated by immunoblot
under non-ligand treated conditions. If GR promoter 1C
methylation played a role in regulating GR expression a
correlation would be expected between degree of methylation,
and protein expression. Indeed, a significant negative correla-
tion was seen.
Figure 6. Treatment with DNA methyltransferase 1 inhibitor, caused an increase in GR expression in DMS 79 cells. (A) GR mRNA
expression normalized to GAPDH in response to 72 hours treatment with 59azadeoxycytidine (59Aza) in DMS 79 cells, GR deficient HEK cells, and GR
expressing A549 cells. (B) Two GR deficient cell lines, DMS 79 and U2OS, were treated with 59Azadeoxycytidine (59Aza) for 72 hours and 5 days
(untreated cells as control). Lysates were then analysed by western blot for GR expression. For DMS 79 cells, the GR expression was normalised
against a tubulin, and plotted as average GR expression plus S.E.M. (n = 3). * indicates p,0.01 compared to vehicle treated control. (C) A panel of
human SCLC cell lines (upper panel) was compared to a panel of non-SCLC cell lines (lower panel) for the response of GR protein to incubation with
59Azadeoxycytidine (59Aza).
doi:10.1371/journal.pone.0024839.g006
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Figure 7. Treatment with 59Azadeoxycytidine restores Gc sensitivity, suppresses BCL2 expression and increases active caspase-3.
(A) Treatment of DMS 79 cells with 59Azadeoxycytidine (59Aza) restores Gc sensitivity. DMS 79 cells treated with 59Aza for 72 hours were transfected
with the TAT3-Luciferase reporter construct. Cells were then incubated overnight with or without 100 nM dexamethasone. Graph shows the average
fold change (dex treated/untreated), (relative light units), (triplicate) plus the S.E.M. (* = p,0.05). DMS 79 cells were also co-transfected with pFUNC1
GR-eYFP (as a positive control) and the TAT3-luciferase reporter construct. Cells were then incubated overnight with or without 100 nM
dexamethasone. Graph shows the average fold change (dex treated/untreated) plus the S.E.M. All results were normalised against a renilla control.
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Studies were aimed at discovering if DNA methylation could
regulate GR expression in hSCLC cells, in a similar manner to
that defined in the rat brain. Treatment with 59Azadeoxycytidine
resulted in a striking induction in GR mRNA and protein in
SCLC cells, although, as expected, there was heterogeneity
amongst the cell lines profiled, with one cell line (COR L24)
showing no induction. Two confounding issues in these studies are
that use of 59azadeoxycytidine exerts a toxic effect on the SCLC
cells, likely as a consequence of regulating multiple tumour
suppressor genes and also that increased GR protein expression
results in increased cell death in SCLC cells [13,14]. In contrast,
augmented GR expression was only seen in one of four non-SCLC
cell lines. Interestingly, in another GR deficient cell line, U2OS,
there was no increase in GR expression, suggesting that loss of GR
expression by promoter methylation may be specific to SCLC.
Analysis of GR mRNA expression showed no induction in two
further cell lines, suggesting a cell-type specific effect. The removal
of methyl marks with 59Azadeoxycytidine resulted in restoration of
glucocorticoid regulation of a simple reporter gene, confirming
expression of a functional receptor and increased glucocorticoid
effects. The increase in GR expression was accompanied by
reacquisition of inhibition of Bcl-2, a key component of the anti-
apoptotic pathway and an increase in cleaved caspase-3, indicative
of apoptosis. This suggests that removal of methyl marks from the
GR results in apoptosis although changes in other tumor
suppressor genes are also likely to play a role in this effect.
Taken together our data support a role for DNA methylation in
regulating GR gene expression in human SCLC cells. This
mechanism is proposed to explain the reduction in GR expression
observed, and the consequent loss of Gc sensitivity. There is a clear
survival advantage for the cancer cells from evading GR integrity,
as restoring GR expression induces apoptosis. Indeed in our study,
treatment with 59Azadeoxycytidine itself resulted in reacquisition
of GR expression, which was followed by specific SCLC cell death.
It seems possible that exposure to the tobacco smoke carcinogen
NNK may play a role in silencing the GR gene by increasing
DNMT1 mediated methylation of the GR promoters lying within
the 59CpG island and thus reducing the role of GR in regulating
apoptosis in the SCLC cells.
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Results are representative of 3 separate experiments. (B) Bcl-2 mRNA expression normalised to GAPDH in response to 72 hours treatment with
59Azadeoxycytidine (59 Aza) in DMS79 and HEK cells. (C) Treatment of cells with Aza and then dexamethasone results in apoptosis. Representative
image of SCLC cells (CORL47) and non-SCLC cells (NCI-H358) treated with Aza as described above. Cells were then treated with dexamethasone for
72 h, fixed and stained for active caspase-3. (D) Demethylation leads to marked increase in Gc mediated apoptosis in SCLC cells compared to non-
SCLC cells. Apoptosis measured by caspase-3 activation after 59Aza and dexamethasone as described above. Grey bars represent cells treated with
dexamethasone, black bars for cells treated with 59Aza and then with dexamethasone. Each cell line was incubated in triplicate and 100 cells counted
to assess % positive staining. Independent student’s t-test * = p,0.05, ** = p,0.01, *** = p,0.001.
doi:10.1371/journal.pone.0024839.g007
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